Vanguard Group Inc Athira Pharma, Inc. Transaction History

Vanguard Group Inc

$5.46 Trillion
Q3 2024

A detailed history of Vanguard Group Inc transactions in Athira Pharma, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,613,063 shares of ATHA stock, worth $935,576. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,613,063

Previous 1,634,433 1.31%

Holding current value

$935,576

Previous $4.33 Million 83.26%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$0.42 - $3.43 $8,975 - $73,299	-21,370 Reduced 1.31%	1,613,063 $725,000
Q1 2024 May 10, 2024	SELL	$2.24 - $4.15 $143,404 - $265,683	-64,020 Reduced 3.77%	1,634,433 $4.48 Million
Q2 2023 Aug 14, 2023	SELL	$2.36 - $3.59 $340,293 - $517,649	-144,192 Reduced 7.83%	1,698,453 $5.01 Million
Q1 2023 May 15, 2023	BUY	$2.26 - $4.22 $10,649 - $19,884	4,712 Added 0.26%	1,842,645 $4.61 Million
Q4 2022 Feb 10, 2023	BUY	$2.76 - $3.71 $16,292 - $21,900	5,903 Added 0.32%	1,837,933 $5.83 Million
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $648,848 - $876,942	221,450 Added 13.75%	1,832,030 $5.44 Million
Q2 2022 Aug 12, 2022	BUY	$2.74 - $13.43 $272,635 - $1.34 Million	99,502 Added 6.58%	1,610,580 $4.91 Million
Q1 2022 May 13, 2022	SELL	$8.96 - $13.51 $216,500 - $326,442	-24,163 Reduced 1.57%	1,511,078 $20.4 Million
Q4 2021 Feb 14, 2022	SELL	$9.17 - $16.39 $974,239 - $1.74 Million	-106,242 Reduced 6.47%	1,535,241 $20 Million
Q3 2021 Nov 12, 2021	BUY	$9.15 - $11.09 $2.51 Million - $3.04 Million	273,884 Added 20.03%	1,641,483 $15.4 Million
Q2 2021 Aug 13, 2021	BUY	$10.24 - $20.87 $14 Million - $28.5 Million	1,367,599 New	1,367,599 $14 Million

Others Institutions Holding ATHA

# of Institutions

Shares Held

16.9M

Call Options Held

112K

Put Options Held

68K

View Full List

About Athira Pharma, Inc.

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $21.9M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

More about ATHA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Athira Pharma, Inc. Transaction History